Blueprint Medicines (NASDAQ:BPMC – Get Free Report) and Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Insider and Institutional Ownership 86.9% of Intra-Cellular […]
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Analyst Ratings This is a summary of […]
Zai Lab (NASDAQ:ZLAB – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Institutional and Insider Ownership 54.0% of Zai […]
Announced positive topline data from the Phase 3 EMERGENT-3 trial of KarXT in schizophrenia in the first quarter of 2023
On track to submit New Drug Application for KarXT in schizophrenia with the. | May 4, 2023
23.02.2023 - Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the .